I’m not sure that’s true for neuro. Proving effectiveness over placebo is where it is hard in such a heterogeneous group. Also phase 2 trials will be complicated. What is the dosing regime, duration, interval, dose. It’s an old molecule but new delivery, effectively starting from scratch. It’s true that non controlled data from 5 patients exists but given the differences I think it’s even less valuable now
I’m not sure that’s true for neuro. Proving effectiveness over...
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.05 |
Change
0.050(0.36%) |
Mkt cap ! $703.5M | |||
| Open | High | Low | Value | Volume |
| $14.00 | $14.07 | $13.89 | $342.4K | 24.49K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1250 | $13.99 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.05 | 97 | 1 |
View Market Depth
| Last trade - 16.10pm 19/08/2024 (20 minute delay) ? |
| CUV (ASX) Chart |